CACA胃癌整合诊治指南(精简版)

中国抗癌协会胃癌专业委员会 徐惠绵 李凯

中国抗癌协会胃癌专业委员会, 徐惠绵, 李凯. CACA胃癌整合诊治指南(精简版)[J]. 中国肿瘤临床, 2022, 49(14): 703-710. doi: 10.12354/j.issn.1000-8179.2022.20220712
引用本文: 中国抗癌协会胃癌专业委员会, 徐惠绵, 李凯. CACA胃癌整合诊治指南(精简版)[J]. 中国肿瘤临床, 2022, 49(14): 703-710. doi: 10.12354/j.issn.1000-8179.2022.20220712
Chinese Society of Gastric Cancer, China Anti-Cancer Association, Humian Xu, Kai Li. China Anti-Cancer Association guidelines for holistic integrative management of gastric cancer (Lite Version)[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 49(14): 703-710. doi: 10.12354/j.issn.1000-8179.2022.20220712
Citation: Chinese Society of Gastric Cancer, China Anti-Cancer Association, Humian Xu, Kai Li. China Anti-Cancer Association guidelines for holistic integrative management of gastric cancer (Lite Version)[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2022, 49(14): 703-710. doi: 10.12354/j.issn.1000-8179.2022.20220712

CACA胃癌整合诊治指南(精简版)

doi: 10.12354/j.issn.1000-8179.2022.20220712
详细信息
    作者简介:

    李凯:专业方向为胃癌亚临床转移早诊与阻断精准治疗

    通讯作者:

    徐惠绵 xuhuimian@126.com

China Anti-Cancer Association guidelines for holistic integrative management of gastric cancer (Lite Version)

More Information
  • 摘要: 胃癌是世界常见恶性肿瘤之一。在中国,胃癌发病率与死亡率均居第3位。近年来,随着诊疗技术的提高及重点人群筛查的实施,胃癌患者的5年生存率逐渐提升,但与日韩等胃癌治疗先进国家相比仍处于较低水平,亟需一部体现中国特色的诊疗指南指导胃癌的防治工作。中国抗癌协会(CACA)整合诊治指南是在总会指导下,由胃癌专委会具体完成的。这是目前为止纳入胃癌相关学科体系最为完整的一部指南,秉承“全人、全身、全程、全息”理念,关注“防-筛-诊-治-康”全程管理,体现学科融合、技术整合、多学科整合诊疗(multi-disciplinary team to holistic integrative medicine,MDT to HIM)的理念,聚焦中国人群的流行病学特征、遗传背景、原创研究成果及诊疗防控特色,纳入国内研究,兼顾医疗可及性,突出中医特色和我国癌症防控经验,体现了“研究证据-医生经验-患者需求”的整合。本指南为全国同道推荐证据类别高、可及性好、最具临床实操指导价值的诊治方案,可以更有针对性的指导中国的胃癌防治工作,改善中国胃癌患者预后,助力健康中国战略。

     

  • [1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3):209-249. doi: 10.3322/caac.21660
    [2] Zhang SW, Yang ZX, Zheng RS, et al. Incidence and mortality of stomach cancer in China, 2013[J]. Zhonghua Zhong Liu Za Zhi, 2017, 39(7):547-552.
    [3] Chen WQ, Zheng RS, Baade PD, et al. Cancer statistics in China, 2015[J]. CA A Cancer J Clin, 2016, 66(2):115-132. doi: 10.3322/caac.21338
    [4] 曹毛毛,陈万青.中国恶性肿瘤流行情况及防控现状[J].中国肿瘤临床,2019,46(3):145-149. doi: 10.3969/j.issn.1000-8179.2019.03.283
    [5] 徐惠绵,季加孚,梁寒,等.胃癌诊治难点中国专家共识(2020版)[J].中国实用外科杂志,2020,40(8):869-904. doi: 10.19538/j.cjps.issn1005-2208.2020.08.01
    [6] Muto M, Yao KS, Kaise M, et al. Magnifying endoscopy simple diagnostic algorithm for early gastric cancer (MESDA-G)[J]. Dig Endosc, 2016, 28(4):379-393. doi: 10.1111/den.12638
    [7] 北京市科委重大项目《早期胃癌治疗规范研究》专家组.早期胃癌内镜下规范化切除的专家共识意见(2018, 北京)[J].中华胃肠内镜电子杂志,2018,5(2):49-60.
    [8] Dong D, Tang L, Li ZY, et al. Development and validation of an individualized nomogram to identify occult peritoneal metastasis in patients with advanced gastric cancer[J]. Ann Oncol, 2019, 30(3):431-438.
    [9] 中国抗癌协会胃癌专业委员会.胃癌腹膜转移防治中国专家共识[J].中华胃肠外科杂志,2017,20(5):481-490. doi: 10.3760/cma.j.issn.1671-0274.2017.05.001
    [10] 中华医学会消化内镜学分会病理学协作组.中国消化内镜活组织检查与病理学检查规范专家共识(草案)[J].中国实用内科杂志,2014,34(9):862-866. doi: 10.7504/nk2014080208
    [11] 国际食管疾病学会中国分会食管胃结合部疾病跨界联盟.食管胃结合部腺癌外科治疗中国专家共识(2018年版)[J].中华胃肠外科杂志,2018,21(9):961-975. doi: 10.3760/cma.j.issn.1671-0274.2018.09.001
    [12] 薛卫成,樊祥山,孟刚.胃癌相关标志物免疫组化指标选择专家共识(2014)[J].临床与实验病理学杂志,2014,30(9):951-953. doi: 10.13315/j.cnki.cjcep.2014.09.001
    [13] Kim ST, Cristescu R, Bass AJ, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer[J]. Nat Med, 2018, 24(9):1449-1458. doi: 10.1038/s41591-018-0101-z
    [14] Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition)[J]. Gastric Cancer, 2021, 24(1):1-21. doi: 10.1007/s10120-020-01042-y
    [15] Tada M, Murakami A, Karita M, et al. Endoscopic resection of early gastric cancer[J]. Endoscopy, 1993, 25(7):445-450. doi: 10.1055/s-2007-1010365
    [16] Ronellenfitsch U, Najmeh S, Andalib A, et al. Functional outcomes and quality of life after proximal gastrectomy with esophagogastrostomy using a narrow gastric conduit[J]. Ann Surg Oncol, 2015, 22(3):772-779. doi: 10.1245/s10434-014-4078-7
    [17] Kurokawa Y, Doki Y, Mizusawa J, et al. Bursectomy versus omentectomy alone for resectable gastric cancer (JCOG1001): a phase 3, open-label, randomised controlled trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(7):460-468. doi: 10.1016/S2468-1253(18)30090-6
    [18] Sasako M, Sano T, Yamamoto S, et al. D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer[J]. N Engl J Med, 2008, 359(5):453-462. doi: 10.1056/NEJMoa0707035
    [19] Wu LL, Zhang C, Liang YX, et al. Risk factors for metastasis to No. 14v lymph node and prognostic value of 14v status for gastric cancer patients after surgery[J]. Jpn J Clin Oncol, 2018, 48(4):335-342. doi: 10.1093/jjco/hyy006
    [20] Kumagai K, Sano T, Hiki N, et al. Survival benefit of “D2-plus” gastrectomy in gastric cancer patients with duodenal invasion[J]. Gastric Cancer, 2018, 21(2):296-302. doi: 10.1007/s10120-017-0733-6
    [21] Chen XZ, Zhang WH, Yang K, et al. Digestive tract reconstruction pattern as a determining factor in postgastrectomy quality of life[J]. World J Gastroenterol, 2014, 20(1):330-332. doi: 10.3748/wjg.v20.i1.330
    [22] Ojima T, Nakamura M, Hayata K, et al. Short-term outcomes of robotic gastrectomy vs laparoscopic gastrectomy for patients with gastric cancer: A randomized clinical trial[J]. JAMA Surg, 2021, 156(10):954-963. doi: 10.1001/jamasurg.2021.3182
    [23] Aizawa M, Honda M, Hiki N, et al. Oncological outcomes of function-preserving gastrectomy for early gastric cancer: a multicenter propensity score matched cohort analysis comparing pylorus-preserving gastrectomy versus conventional distal gastrectomy[J]. Gastric Cancer, 2017, 20(4):709-717. doi: 10.1007/s10120-016-0644-y
    [24] 胡祥,田大宇,曹亮.残胃癌的淋巴结转移特点及外科治疗[J].中华消化外科杂志,2010,9(3):203-206. doi: 10.3760/cma.j.issn.1673-9752.2010.03.015
    [25] Katai H, Ishikawa T, Akazawa K, et al. Optimal extent of lymph node dissection for remnant advanced gastric carcinoma after distal gastrectomy: a retrospective analysis of more than 3000 patients from the nationwide registry of the Japanese Gastric Cancer Association[J]. Gastric Cancer, 2020, 23(6):1091-1101. doi: 10.1007/s10120-020-01081-5
    [26] Greally M, Agarwal R, Ilson DH. Optimal management of gastroesophageal junction cancer[J]. Cancer, 2019, 125(12):1990-2001.
    [27] Goto H, Tokunaga M, Miki Y, et al. The optimal extent of lymph node dissection for adenocarcinoma of the esophagogastric junction differs between Siewert type Ⅱ and Siewert type Ⅲ patients[J]. Gastric Cancer, 2014: 18(2):375-381.
    [28] Kurokawa Y, Takeuchi H, Doki Y, et al. Mapping of lymph node metastasis from esophagogastric junction tumors: A prospective nationwide multicenter study[J]. Ann Surg, 2021, 274(1):120-127. doi: 10.1097/SLA.0000000000003499
    [29] Yoshida K, Kodera Y, Kochi M, et al. Addition of docetaxel to oral fluoropyrimidine improves efficacy in patients with stage Ⅲ gastric cancer: interim analysis of JACCRO GC-07, a randomized controlled trial[J]. J Clin Oncol, 2019, 37(15):1296-1304. doi: 10.1200/JCO.18.01138
    [30] Park SH, Lim DH, Sohn TS, et al. A randomized phase Ⅲ trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial[J]. Ann Oncol, 2021, 32(3):368-374. doi: 10.1016/j.annonc.2020.11.017
    [31] Stiekema J, Trip AK, Jansen EP, et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy[J]. Ann Surg Oncol, 2014, 21(4):1107-1114. doi: 10.1245/s10434-013-3397-4
    [32] Lee J, Lim DH, Kim S, et al. Phase Ⅲ trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial[J]. J Clin Oncol, 2012, 30(3):268-273. doi: 10.1200/JCO.2011.39.1953
    [33] Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial[J]. Lancet, 2012, 379(9813):315-321.
    [34] Li T, Chen L. Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer[J]. Zhonghua Wei Chang Wai Ke Za Zhi, 2011, 14(2):104-106.
    [35] Kang YK, Yook JH, Park YK, et al. PRODIGY: a phase Ⅲstudy of neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 versus surgery and adjuvant S-1 for resectable advanced gastric cancer[J]. J Clin Oncol, 2021, 39(26):2903-2913. doi: 10.1200/JCO.20.02914
    [36] Al-Batran SE, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial[J]. Lancet, 2019, 393(10184):1948-1957. doi: 10.1016/S0140-6736(18)32557-1
    [37] Ochiai T, Sato H, Sato H, et al. Randomly controlled study of chemotherapy versus chemoimmunotherapy in postoperative gastric cancer patients[J]. Cancer Res, 1983, 43(6):3001-3007.
    [38] Sumpter K, Harper-Wynne C, Cunningham D, et al. Report of two protocol planned interim analyses in a randomisedmulticentre phase Ⅲ study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF[J]. Br J Cancer, 2005, 92(11):1976-1983. doi: 10.1038/sj.bjc.6602572
    [39] Graziano F, Catalano V, Baldelli AM, et al. A phase Ⅱ study of weekly docetaxel as salvage chemotherapy for advanced gastric cancer[J]. Ann Oncol, 2000, 11(10):1263-1266.
    [40] Takashima A, Shitara K, Fujitani K, et al. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase Ⅲ ABSOLUTE trial[J]. Gastric Cancer, 2019, 22(1):155-163. doi: 10.1007/s10120-018-0838-6
    [41] Stahl M, Walz MK, Stuschke M, et al. Phase Ⅲcomparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction[J]. J Clin Oncol, 2009, 27(6):851-856. doi: 10.1200/JCO.2008.17.0506
    [42] Leong T, Smithers BM, Michael M, et al. TOPGEAR: a randomised phase Ⅲtrial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG)[J]. BMC Cancer, 2015, 15:532. doi: 10.1186/s12885-015-1529-x
    [43] Van Cutsem E, Moiseyenko VM, Tjulandin S, et al. Phase Ⅲ study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group[J]. J Clin Oncol, 2006, 24(31):4991-4997.
    [44] Wang JW, Xu RH, Li J, et al. Randomized multicenter phaseⅢstudy of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer[J]. Gastric Cancer, 2016, 19(1):234-244. doi: 10.1007/s10120-015-0457-4
    [45] Hofheinz RD, Haag GM, Ettrich TJ, et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: final results of the PETRARCA multicenter randomized phase Ⅱ trial of the AIO[J]. J Clin Oncol, 2020, 38(15_Suppl):4502. doi: 10.1200/JCO.2020.38.15_suppl.4502
    [46] Janjigian YY, Maron SB, Chatila WK, et al. First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial[J]. Lancet Oncol, 2020, 21(6):821-831. doi: 10.1016/S1470-2045(20)30169-8
    [47] Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med, 2015, 372(26):2509-2520. doi: 10.1056/NEJMoa1500596
    [48] Pietrantonio F, Miceli R, Raimondi A, et al. Individual patient data Meta-analysis of the value of microsatellite instability As a biomarker in gastric cancer[J]. J Clin Oncol, 2019, 37(35):3392-3400. doi: 10.1200/JCO.19.01124
    [49] Zhang ZN, Cheng SY, Gong JF, et al. Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series[J]. Eur J Surg Oncol, 2020, 46(10):e33-e39.
    [50] Chun JH, Kim HK, Lee JS, et al. Weekly irinotecan in patients with metastatic gastric cancer failing cisplatin-based chemotherapy[J]. Jpn J Clin Oncol, 2004, 34(1):8-13. doi: 10.1093/jjco/hyh006
    [51] Kanat O, Evrensel T, Manavoglu O, et al. Single-agent irinotecan as second-line treatment for advanced gastric cancer[J]. Tumori, 2003, 89(4):405-407. doi: 10.1177/030089160308900411
    [52] Pang XH, Wei WQ, Leng WB, et al. Radiotherapy for gastric cancer: a systematic review and meta-analysis[J]. Tumour Biol, 2014, 35(1):387-396.
    [53] 国家卫生健康委员会.胃癌诊疗规范(2018年版)[J].中华消化病与影像杂志(电子版),2019,9(3):118-144.
    [54] 石汉平. 营养治疗的疗效评价[J]. 肿瘤代谢与营养电子杂志, 2017, 4(4):364-370.
    [55] Muscaritoli M, Arends J, Bachmann P, et al. ESPEN practical guideline: clinical Nutrition in cancer[J]. Clin Nutr, 2021, 40(5):2898-2913.
    [56] Braga M, Ljungqvist O, Soeters P, et al. ESPEN guidelines on parenteral nutrition: surgery[J]. Clin Nutr, 2009, 28(4):378-386. doi: 10.1016/j.clnu.2009.04.002
    [57] Kehlet H, Wilmore DW. Multimodal strategies to improve surgical outcome[J]. Am J Surg, 2002, 183(6):630-641. doi: 10.1016/S0002-9610(02)00866-8
    [58] Varadhan KK, Neal KR, Dejong CH, et al. The enhanced recovery after surgery (ERAS) pathway for patients undergoing major elective open colorectal surgery: a meta-analysis of randomized controlled trials[J]. Clin Nutr, 2010, 29(4):434-440. doi: 10.1016/j.clnu.2010.01.004
    [59] Liu XX, Jiang ZW, Wang ZM, et al. Multimodal optimization of surgical care shows beneficial outcome in gastrectomy surgery[J]. JPEN J Parenter Enteral Nutr, 2010, 34(3):313-321. doi: 10.1177/0148607110362583
  • 加载中
计量
  • 文章访问数:  1110
  • HTML全文浏览量:  369
  • PDF下载量:  632
  • 被引次数: 0
出版历程
  • 收稿日期:  2022-05-10
  • 录用日期:  2022-06-17
  • 修回日期:  2022-05-23

目录

    /

    返回文章
    返回